By Brazil Stock Guide – Hypera Pharma (HYPE3) said it expects to begin selling semaglutide-based weight-loss medications in Brazil soon after the drug’s patent expires in March 2026, signaling confidence that the Anvisa approval process will align with its plans. The company could become one of the first local players in a segment worth billions of reais annually.
According to Reuters, CEO Breno de Oliveira told analysts after the company’s third-quarter earnings release that the regulatory process has been slower than anticipated. “Anvisa’s approval times have lengthened compared to when the business cases were built… but we are optimistic that the queue will shorten, allowing us to bring launches forward,” Oliveira said.
The executive highlighted that the market for GLP-1 analog drugs, which includes semaglutide, generates around R$10 billion a year, or 8% of Brazil’s entire pharmaceutical market. “Our goal is to enter this segment with branded products, a medical detailing team, and better prices and margins,” he said, noting that production partners have not flagged any potential capacity constraints.
Oliveira added that cooler-than-usual weather in October, particularly in São Paulo, has supported demand for cold and flu medicines. “Sales growth this quarter is similar to that seen in the third quarter,” he noted. The company reported an 8.3% increase in sell-out sales year over year, driven by seasonal categories.
At 12:09 p.m. on Tuesday (28), Hypera’s shares rose 2.7% to R$23.97, leading gains on the Ibovespa, which was up 0.8%.
In the institutional market—which includes government contracts and healthcare groups—Oliveira said Hypera is pursuing “a slightly more competitive stance” in pricing for certain molecules where it has idle capacity. Over the medium term, the company plans to expand its private-sector share and enter strategic areas such as oncology, with its first cancer drugs expected to debut in 2026.
Leave a Reply